NCT00768664 - Open-Label Trial Of Oral PF-00299804 By Continuous Dosing In Patients With Recurrent Or Metastatic Head And Neck Squamous Cell Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 4, 2008

Primary Completion Date

May 5, 2010

Study Completion Date

April 18, 2012

Conditions

Head and Neck Neoplasms

Interventions

DRUG

PF-00299804

45 mg by continuous oral dosing

Trial Locations (10)

BC Cancer Agency, Vancouver Centre, Vancouver

Fairmont Medical Building, Vancouver

Hamilton Health Sciences, Hamilton

London Health Sciences Centre, London

London Regional Cancer Centre, London

The Ottawa Hospital Cancer Centre, Ottawa

The Ottawa Hospital Cancer Centre, Ottawa

Sunnybrook Health Sciences Centre: Odette Cancer Center, Toronto

Princess Margaret Hospital, Toronto

Hopital Notre-dame du CHUM - Oncology Center, Montreal